Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver

Huberman frames the whole episode with a ladder metaphor rather than a drug-by-drug catalogue: diet and exercise at the bottom, supplements next, prescription hormones such as growth hormone and testosterone above that. Peptides, he argues, occupy the space in between, because they can act on hormonal pathways without the drawback he attributes to exogenous hormones. His stated reason is mechanistic: peptides "can augment specific, in fact, multiple processes within the brain and body to augment health, but they don't tend to operate in that negative feedback cycle by shutting down one's own endogenous production." That distinction, not potency, is the organising claim of the conversation, and it is worth testing against each compound discussed later.

Koniver supplies the definition and immediately narrows it to a size threshold rather than a functional one. Peptides are amino acid chains, and "We call it a peptide if it's 40 amino acids or less," with anything longer counted as a protein. He also gives a sense of scale: "The body makes, I think, last I read, 300,000 peptides," of which roughly 250 have been used therapeutically. The hedging in that sentence ("I think, last I read") is itself informative. Much of what follows rests on clinical observation and rough recollection rather than on a body of trial data, which is the recurring limitation of the episode.

Huberman is explicit that the discussion is time-stamped. He notes that three peptides had just been restored to prescription status shortly before release: CJC-1295 and Ipamorelin, both growth hormone secretagogues, plus thymosin beta-alpha. The recorded conversation itself, however, describes an earlier regulatory state in which the FDA had removed several compounds, so listeners are hearing a snapshot that had already been partly superseded. He also states the standing caveats up front: side effects, the problem of sourcing clean peptides, and the need to work with a board-certified physician.

Koniver's account of how semaglutide became a weight-loss drug is a case study in off-label prescribing. It was approved for type 2 diabetes and glucose control; weight loss appeared as an observed side effect and then became the marketing story. He generalises from there: "most of the medicines prescribed, particularly in America, are prescribed off-label." His defence of the practice is legal and professional rather than evidential: "I'm allowed to prescribe any drug for any reason I want, as long as it's been approved for something," qualified by a warning against being "cavalier." The sequence he describes for semaglutide runs from lowering blood sugar in diabetics, to weight loss in diabetics with insulin resistance, to weight loss in people without diabetes at all.

The most contestable part of the interview is Koniver's stated philosophy of sequencing. Rather than requiring lifestyle change first, he prefers to produce a result first so that motivation follows, using a racing analogy: he likes to help people "win the race first, which then helps them motivate to train for the next race." He acknowledges this "goes against the grain of conventional medicine," which asks for the training before the race. His evidence is a single clinical anecdote from the day before recording, a successful Los Angeles client who said "You've changed my life" and reported better workouts, better fit of clothes, and enthusiasm about waking up. That is a real outcome for that patient, but it is also exactly the kind of testimony that cannot distinguish drug effect from attention, cost, or expectation.

On the specific criticism that GLP-1 drugs cost lean mass, Koniver concedes the premise and disputes the magnitude under his protocol. He and Huberman agree resistance training helps, and Koniver adds compounding as the lever: because they obtain compounded semaglutide and mostly tirzepatide, they can "use basically micro-dosages and start very low in terms of dosage and go slowly." The operational threshold he gives is rate-based: "as long as people are losing two pounds or less a week, they're not losing the muscle mass." That is a clinically plausible rule of thumb, but he presents it as something "we've found" rather than as a measured body-composition result, and no DEXA or similar data is offered.

The failure modes he describes are the ones a slow titration is meant to avoid: rapid loss of fifteen pounds in three weeks, immediate regain after stopping, and hollowed facial fat that he names by its popular label, "Ozempic face," noting that "that fat takes a while to come back." He also reports benefits beyond weight: cognitive improvement, lower inflammation, and reduced markers in autoimmune patients.

Huberman presses on mechanism, asking whether the anti-inflammatory effect is direct on immune pathways or indirect via adipose tissue loss. Koniver declines to choose and instead lists three candidates, adding mood and self-perception as a third: better appearance feeding forward into behaviour. "I think it's all of the above," he says, and concedes "that's going to be hard to dissect." The supporting case is a 50-year-old patient with Hashimoto's thyroiditis whose thyroid peroxidase antibodies fell after GLP-1 use was added to probiotics and other immune support. Koniver is candid about the explanatory gap: "I don't have a great way of explaining it, but there's something going on that's very positive." Antibody reduction alongside weight loss and improved wellbeing leaves the causal direction unresolved, and he does not claim otherwise.

The disagreement Huberman sets up is between enthusiasm and concern about dependency, cost, and the potency of lifestyle measures. Koniver does not reject the concern; he reports having held it. He says he initially worried about excessive weight loss and lifelong dependence, and his position now is narrower than advocacy: "I'm not saying it has to be the rest of their life, but when something works, and as far as I can tell, is very safe, I think it's worth discussing." The qualifier "as far as I can tell" carries the weight here, since the safety claim is grounded in his own practice rather than in the trial literature he never cites.

Huberman states the evidential situation before asking anything about use: BPC-157, or Body Protection Compound-157, has "a lot of animal data, very few, if any, clinical studies on humans." Koniver agrees with that assessment in a single word and then describes usage anyway. BPC is, by his account, "the most utilized peptide that we've used," given to almost every patient, on the rationale that it is "very anti-inflammatory" and that adults are stiff, sore, training, or managing chronic disease. His volume claim is large, "thousands upon thousands of patients," but the outcome measure is patient report of reduced stiffness and joint pain.

The dosing history he gives is a climb driven by observation, not by dose-finding trials: starting at "500 micrograms a day" and eventually reaching "5,000 micrograms a day," on a schedule of "five days on, two days off." He reports success in post-viral cases and argues that "anyone who's working out on a regular basis" would benefit. The safety inference is comparative rather than measured: unlike high-dose antioxidants, which he says may blunt exercise adaptation, "I don't think that's happening with BPC." Huberman supplies the physiological reason that distinction matters, noting that cold water immersion in the four to eight hours after resistance training can limit hypertrophy and strength gains because the adaptation itself is driven by an inflammatory response. Whether BPC actually threads that needle is asserted, not shown.

A practical surprise in the interview is the route of administration. Koniver expected oral BPC to serve gut problems and injected BPC to serve everything else, and found the opposite: "I've certainly observed that clinically," he says of oral use for gastrointestinal conditions, but "if we're injecting, it actually works better than the oral." He extends the logic against local injection, telling patients not to inject an injured elbow because "It's going to work systemically." Subcutaneous delivery with a 30 or 31 gauge insulin needle in the abdomen or glute is presented as sufficient, with the claim that benefit then appears across all joints rather than only the injured one.

Huberman articulates the mechanistic puzzle clearly: BPC-157 is reported to initiate fibroblast migration, yet a few centimetres of volume near the umbilicus is said to find a torn Achilles. He flags the anecdotal nature of the surrounding lore, including talk about an Olympic athlete who returned from a torn Achilles within weeks, and labels it "just chatter and fog." Koniver's answer is an analogy rather than a mechanism: he recalls reading a study in which radiographically tagged intravenous stem cells aggregated at a fracture site within 24 hours, and generalises to "an innate human-like design and intelligence, which I believe in." He offers to find the paper, does not name it, and the audience is left with a citation-shaped gap where the strongest evidence should be.

The clinical niche Koniver claims for BPC is connective tissue at the muscle-bone junction, on the reasoning that people build muscle but neglect tendons and ligaments, which is where strain, sprain, and tearing occur. He draws a sharp contrast with steroids: "We would never inject steroids into a tendon. You damage the tendon." BPC, by contrast, is mixed with platelet-rich plasma or platelet-rich fibrin and, he says, produces healing within days, summarised as "It's super safe, and it's amazing for people." The confidence of that closing line sits uneasily beside the animal-only evidence base both men had acknowledged minutes earlier.

Huberman introduces the sourcing problem from personal concern rather than from data, warning about gray-market BPC bought "on the internet" from vendors whose products are labelled "Not for human or animal consumption, for research purposes only." The core issue he identifies is that potency and purity are unverified, and that many such products contain lipopolysaccharide, which is inflammatory. Koniver does not dispute this; he redirects to the parallel case of anabolic steroids, where nandrolone (Deca) can be prescribed legitimately while trenbolone and similar compounds cannot be obtained from a physician or a reputable US website.